These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37737688)

  • 21. Impact of checkpoint blockade on cancer vaccine-activated CD8+ T cell responses.
    Santos PM; Adamik J; Howes TR; Du S; Vujanovic L; Warren S; Gambotto A; Kirkwood JM; Butterfield LH
    J Exp Med; 2020 Jul; 217(7):. PubMed ID: 32369107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Programmed death ligand-1 induction restrains the cytotoxic T lymphocyte response against microglia.
    Chauhan P; Hu S; Prasad S; Sheng WS; Lokensgard JR
    Glia; 2021 Apr; 69(4):858-871. PubMed ID: 33128485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacy.
    Jeon D; Hill E; Moseman JE; McNeel DG
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38702146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dendritic cells recruit T cell exosomes via exosomal LFA-1 leading to inhibition of CD8+ CTL responses through downregulation of peptide/MHC class I and Fas ligand-mediated cytotoxicity.
    Xie Y; Zhang H; Li W; Deng Y; Munegowda MA; Chibbar R; Qureshi M; Xiang J
    J Immunol; 2010 Nov; 185(9):5268-78. PubMed ID: 20881190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.
    Ahrends T; Bąbała N; Xiao Y; Yagita H; van Eenennaam H; Borst J
    Cancer Res; 2016 May; 76(10):2921-31. PubMed ID: 27020860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Flt3L-mobilized dendritic cells bearing H2-Kbm1 apoptotic cells do not induce cross-tolerance to CD8+ T cells across a class I MHC mismatched barrier.
    del Rio ML; Cote-Sierra J; Rodriguez-Barbosa JI
    Transpl Int; 2011 May; 24(5):501-13. PubMed ID: 21276089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
    Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
    Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression.
    Pierini S; Mishra A; Perales-Linares R; Uribe-Herranz M; Beghi S; Giglio A; Pustylnikov S; Costabile F; Rafail S; Amici A; Facciponte JG; Koumenis C; Facciabene A
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade.
    Singh S; Roszik J; Saini N; Singh VK; Bavisi K; Wang Z; Vien LT; Yang Z; Kundu S; Davis RE; Bover L; Diab A; Neelapu SS; Overwijk WW; Rai K; Singh M
    Front Immunol; 2022; 13():794684. PubMed ID: 35720386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro tumor-pulsed or in vivo Flt3 ligand-generated dendritic cells provide protection against acute myelogenous leukemia in nontransplanted or syngeneic bone marrow-transplanted mice.
    Pawlowska AB; Hashino S; McKenna H; Weigel BJ; Taylor PA; Blazar BR
    Blood; 2001 Mar; 97(5):1474-82. PubMed ID: 11222396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour.
    Song S; Zhang K; You H; Wang J; Wang Z; Yan C; Liu F
    Clin Exp Immunol; 2010 Oct; 162(1):75-83. PubMed ID: 20735440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
    Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gemcitabine-mediated depletion of immunosuppressive dendritic cells enhances the efficacy of therapeutic vaccination.
    Repáraz D; Ruiz M; Silva L; Aparicio B; Egea J; Guruceaga E; Ajona D; Senent Y; Conde E; Navarro F; Barace S; Alignani D; Hervás-Stubbs S; Lasarte JJ; Llopiz D; Sarobe P
    Front Immunol; 2022; 13():991311. PubMed ID: 36300124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma.
    Reilley MJ; Morrow B; Ager CR; Liu A; Hong DS; Curran MA
    J Immunother Cancer; 2019 Nov; 7(1):323. PubMed ID: 31771649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
    Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines.
    Ji S; Lee J; Lee ES; Kim DH; Sin JI
    Hum Vaccin Immunother; 2021 Jul; 17(7):1910-1922. PubMed ID: 33522416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
    Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
    J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Checkpoint inhibitor-expressing lentiviral vaccine suppresses tumor growth in preclinical cancer models.
    Tada T; Norton TD; Leibowitz R; Landau NR
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38658032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.